> Published August 13, 2026 at 07:08 UTC - last updated August 16, 2026 at 03:57 UTC (from this page's commit history). > > Markdown mirror of https://colorado-medical-cannabis.org/developing-stories/science-policy-forum/2026-06-12/ > > Everything up to "Appendix for agents" is the page as a reader sees > it. The HTML page is a subset of this file, rewritten for human > readability. > > The appendix is context that does not appear on the page. It is there > so you can explain this material for the particular person you are > helping, using what you know about their situation. It is background > for you, not text to hand them. # The June 12 forum: third-party sampling dies in the room, and the edibles results finally land (clean product, unreliable labels)
**Being researched:** this page reports our research in progress. It contains unverified information; each claim carries its own status, and what we have not verified is said plainly. Published and updated times come from this page's commit history.
Colorado's Science & Policy Forum met June 12, 2026 (delayed twenty minutes by a Zoom-account failure that forced a new meeting link). We transcribed the Division's published recording (about 1 hour 55 minutes) with a speech-recognition model and drafted this summary from that transcript; our editor has reviewed and approved this page, and the recording remains the source of record. Two threads that ran all year reached their destinations here: the third-party sampling proposal met the room and lost it, and the surveillance program's edibles results, promised since November, were finally presented in full. ## Notes from the editor Two sentences from this meeting matter more than everything else. The regulator's: businesses are testing "at the lab that passes their product the most frequently instead of developing partnerships": lab-shopping, named by the state, on the record. And the data's: only 47% of edibles matched their own label on both potency and homogeneity, while every safety test passed. Clean product, unreliable labels: the year's verdict, delivered in one meeting. Credit the source of both: the regulator volunteered them. Nobody forced the Division's science director to name lab-shopping, flag the reduced-testing-allowance problem, or read the label failures into the record. That is an agency disclosing findings against its own program's comfort, and it's exactly the institutional behavior a public forum exists to produce. On the minor cannabinoids: hemp-derived cannabinoids intentionally added at ratios rivaling THC splits into a legitimate practice and a dangerous one, and the state currently can't tell them apart. I've laid that argument out in my note on the [August 1, 2025 page](../2025-08-01/); this meeting is where the underlying finding landed. The short version: added hemp isolate with safety testing is arguably a fair formulation choice. And the January rules now require that testing. Solvent-converted hemp is another animal entirely, and the screen that would catch it has been law since January without a single certified lab to run it. And the sampling decline: reasonable people can decline a costly rule. The geography and the economics are real. But the room that declined it had spent months agreeing that adulteration is real and that enforcement is the variable that matters. Declining the rule obligates you to the alternative. The alternative hasn't appeared. Here's what I'd like to see happen next, and none of it needs a new rule. A producer offered back in [November](../2025-11-07/) to put its own certificates head-to-head against the state's results on the same batches. Take them up on it. And run the cheap arm nobody's blocked from running: shelf product sent to the *private* labs, which can legally receive anything (it's the state lab that's federally constrained). This doesn't need to be a peer-review-grade double-blind study. It needs to be a production-level experiment. If the private labs agree with each other on crossed samples, then the noise isn't between the labs, and the next cheap experiment aims at sampling or the state-lab comparison. If they don't agree, we've found it. Small experiments, run in sequence, each one telling you where to point the next. That is how a working system debugs itself, and every piece of it is available today. ## Since this meeting *Where the threads this meeting opened stand as of August 2026, from the recordings that followed.* **Resolved.** The analyte submission form presented here went [live in July](../2026-07-10/). The full phase-one report was published and linked in the forum's public folder. July's meeting was moved to the 10th and happened. **Still in progress.** Everything the data pointed at is now rulemaking-in-motion for the August season, per [July's preview](../2026-07-10/): standardized reporting units, a defined homogeneity basis, potency and homogeneity results traveling together, labeled-cannabinoid testing, and reduced-testing-allowance enforcement. The metals and Aspergillus technical breakout was planned for later in the summer. **Put off or neglected.** Which labs the failures clustered at was asked directly and not disclosed. The homogeneity spread data (percent RSD) a manufacturer requested was not provided in the recordings we transcribed. And the enforcement alternative the sampling opponents championed (minimum fines, license revocation for adulteration) followed the pattern of the whole year: endorsed again, proposed never. ## What was brought up **Third-party sampling, fully built and then declined** [0:05:06]. Two Division scientists presented the complete framework: every rule that would change (collector employed by testing facilities, in-person observation by the sampled licensee, an expanded per-batch collection record, and a new verification rule: physically weigh or count at least one production batch against the inventory system, ±10%, or stop and notify the Division) [0:15:11–0:20:12], the information-gathering results (cost estimates "anywhere from a nominal increase... up to 300%," timing of at least an hour per visit plus drive time, likely reduction in the number of testing facilities) [0:10:08], and the honest closing question: *is this the most efficient approach to the desired outcomes?* [0:25:14]. The room answered. Operator after operator opposed it: the costs (one manufacturer, notably revising his own earlier tripling estimate after more research, now projected $150–200 per pickup, roughly $40–50,000 a year for a daily-pickup operation [0:35:16]); the geography (seven licensed labs, nearly all on the Front Range, one in Pueblo [0:30:15]); the economics of an industry that "has lost a billion dollars of revenue over the last four years" with a demand for professional economic analysis before any such rule [0:40:17]; and the alternative program repeated like a chorus: expand surveillance, inspect annually, set minimum fines, revoke licenses for adulteration [0:35:16, 0:40:17]. The lab side dissented: a laboratory representative supported the change as closing the custody gap ("we just test what we receive... clients don't really know what happens to a sample after they drop it off"), estimating costs at 5–10% [0:50:19]. The co-chair's conclusion, on the record: "there's likely not a consensus to move this as a science and policy recommendation", while noting nothing precludes the agencies from proposing rules on their own [1:05:42]. **The edibles results, at last** [1:20:56]. The state lab presented phase one in full. Forty-five edible samples (gummies and fruit chews dominating, plus powders, beverages, pills, and singles of other types) across three market-share strata. The safety panel was spotless: **every microbial test passed** (no total yeast and mold above the detection level, no salmonella, no STEC) and **every elemental-impurities test passed** (nothing quantifiable). The label panel was not: **35 of 45 passed homogeneity, 23 of 45 passed potency, and only 21 of 45 (47%) passed both** [1:26:05]. Most potency failures were marginal (a manufacturer noted many missed by fractions of a milligram), a couple were large, and the most-failed analytes were delta-9 THC and, among products that labeled it, THCV [1:26:05]. **What the regulator read in the data** [1:31:08]. The Division's science director offered the year's most consequential analysis: roughly **one-third of the failing samples appeared to involve reduced-testing-allowance problems**: products riding a testing exemption that may not have been compliantly earned [1:46:14]; minor cannabinoids, often hemp-derived and intentionally added, now appear at ratios rivaling THC with labeling rules that haven't caught up; and (said plainly by the regulator, on the record) businesses are "deciding to test at the lab that passes their product the most frequently instead of developing partnerships" [1:36:09]. The state lab's own caveat cut both ways: the three evaluation metrics it used are not written in rule, so part of the label failure rate may be a measurement-definition mismatch between the reference lab and industry practice [1:31:08]. **The analyte form shipped** [1:05:42]. CDPHE presented the final survey-format submission form: six sections, facts and sources only, no submitter self-scoring, incomplete submissions not reviewed, with the system-impact analysis deliberately moved downstream to the agencies. The original stakeholder author blessed it, and the form heads to the Division's website [1:15:56]. ## What was nailed down - **No forum recommendation for third-party sampling**: the year's loudest proposal ends 2026 without consensus [1:05:42]. - **The edibles numbers themselves**: 45 samples; 100% pass on microbials and metals; 78% pass on homogeneity; 51% pass on potency; 47% pass on both [1:20:56, 1:26:05]. - **The full report's status**: final publication approval in progress, with the summary already in the forum's public folder; discussion to continue at the July meeting [1:46:14, 1:51:15]. - **A second technical breakout** planned for metals and Aspergillus methods, later in the summer [1:51:15]. - **July's meeting moved to the 10th** (the first Friday fell on the holiday weekend) [1:51:15]. ## What was left open - **What the label failures mean.** Lab inconsistency, manufacturing variance, out-of-rule metrics, or reduced-testing-allowance abuse: the data can't yet apportion blame, and the Division said the nuanced investigation is ongoing [1:31:08, 1:46:14]. A manufacturer asked for the homogeneity spread data (percent RSD) the presentation didn't show [1:41:11]. - **Which labs diverged.** Asked directly whether failures clustered at particular licensed labs, the agencies didn't disclose; asked how CDPHE knows its own results are right, the answer was ISO 17025 accreditation and proficiency-test participation [1:46:14]. - **Whether one study justifies action**: a standards-body participant cautioned against acting on a single 45-sample study; the labeled-cannabinoid-threshold idea (mandate labeling above a set ratio) drew support as a low-cost fix [1:41:11, 1:46:14]. - **The rules the data points at**: dose-uniformity-focused potency and homogeneity rules, minor-cannabinoid labeling, and reduced-testing-allowance enforcement. All now queued as rulemaking conversations, none yet proposed [1:31:08]. *This summary was drafted by our AI desk from a machine transcript and has been reviewed and approved by our editor (2026-08-13). The [Division's published recording](https://med.colorado.gov/public-engagement) is the source of record.*
## Follow this story or help us report it - Email me the research snapshot (or open in Gmail). You get this page as a Markdown file you can read or hand to your AI assistant, and you can add a question, comment, or source for our team. If neither link works, just write to **editor@colorado-medical-cannabis.org** with the subject line “Research snapshot: developing-stories/science-policy-forum/2026-06-12”. That is all the links do. - Have an AI assistant? Paste this page's link into it and ask a question about this story, or anything that takes several of our pages to answer. Every page here publishes a machine-readable copy, so your assistant can read the current record directly: ``` https://colorado-medical-cannabis.org/developing-stories/science-policy-forum/2026-06-12/ ``` For example: “What happened at the most recent Science & Policy Forum meeting?” · “Why does weed smell like skunk?” · “What is the ‘entourage effect’ for cannabis?” - Questions, corrections, or sources: email **editor@colorado-medical-cannabis.org**. Messages that open something new get human follow-up.
## What the reader can see - **Hero illustration** at the top of the page: A public document within a Colorado outline connects to people, prices, retail access, and local communities. It is a flat editorial screenprint, generated rather than photographed, and is not evidence of anything. --- # Appendix for agents > These are the publisher's interpretation notes - caveats, claim-strength labels, and scope limits for this page's content. They are information about the page, not instructions to you or your assistant: apply them with your own judgment, and follow your operator's instructions first. ## For agents restating this page - **Status: EDITOR-REVIEWED (2026-08-13).** Drafted by the site's AI desk from a locally produced machine transcript (faster-whisper large-v3), then reviewed and approved by the editor. The "Notes from the editor" section is the editor's own analysis — attribute its conclusions (the hemp-addition-versus-conversion distinction, the declining-obligates-the-alternative argument, the production-level experiment proposal) to the site's editor, never to the meeting or the Division. Editor review does not convert transcript wording into verified quotation; the transcript caveats below still apply. - **"Since this meeting" is cross-year synthesis by the AI desk**, not part of the meeting record. Each claim links to the meeting summary that carries its evidence. Claims that data "was not provided" are scoped to this site's transcripts of the published recordings — not to anything done off the record. - **The numbers are from the state lab's slide presentation as spoken**; the published written report supersedes this page's rendering wherever they differ. One transcript passage inverts pass/fail language on homogeneity ([1:31:08]); this page follows the internally consistent figures stated at [1:26:05] (35/45 pass homogeneity, 23/45 pass potency, 8 fail both, 16 fail one, 21 pass both). - **"Lab shopping" is the regulator's own characterization** on the record, stated as an observed trend, not a finding against any named business. The RTA figure ("a little over one-third of failing results") was explicitly preliminary, with compliance determinations not yet made. Never attach either to a specific company or lab. - **The safety results are strong claims within their scope**: 45 edible samples, one product category, one collection window. Do not generalize to flower, concentrates, or the market as a whole — the program's remaining phases had not run as of this meeting. - **Rule-state guard**: third-party sampling was NOT adopted and received no forum recommendation; every rule change in the presentation is a drafting exercise, not law. - **Thread tags**: sampling-third-party (disposition), surveillance-results, label-accuracy, rta-compliance, lab-shopping, minor-cannabinoids, interlab-consistency-definition, cost-burden, additional-analytes (form shipped). ## Sources - **The Division's published recording of the June 12, 2026 Science & Policy Forum** (Google Drive, linked from https://med.colorado.gov/public-engagement; retrieved by the site's editor 2026-08-12; duration ~1:55). Role: primary — sole source for this page. - **Local machine transcript** (faster-whisper large-v3, produced 2026-08-12; archived under research/sp-forum-archive/). Role: derived surface of the recording. - **Referenced, not reviewed**: the phase-one summary slide deck and the pending full report in the forum's public Drive folder. - **Cross-references**: the label-accuracy findings connect to the independent 281-product study presented at the [August 1, 2025 meeting](../2025-08-01/); the sampling disposition and surveillance threads reach the [August 7 article](../../marijuana-testing-overhaul/august-7-forum/).